MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced the publication of study results showing that GRNOPC1, the company’s human embryonic stem cell (hESC)-based therapeutic for the treatment of spinal cord injury, evades direct attack by the human immune system in vitro.
